Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: Journal Article
Number of items: 3.

Journal Article

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O'Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2019). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 19 (11). S. 715 - 729. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Kipps, Thomas J., Hillmen, Peter, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Grosicki, Sebastian, Coutre, Steven E., Barrientos, Jacqueline C., Barr, Paul M., Janssens, Ann, Byrd, John C., O'Brien, Susan M., Fraser, Graeme, Jaeger, Ulrich, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Salman, Mariya, Solman, Isabelle, Cheng, Mei, Phelps, Charles, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2016). 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M. and Stilgenbauer, Stephan (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J. Clin. Oncol., 37 (16). S. 1391 - 1405. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Sun Jan 24 02:09:17 2021 CET.